IVBM

Philadelphia oncology leaders tackle gaps in biomarker testing, breast cancer advances, myeloma innovation, and clinical trial equity.

Experts discussed value-based oncology care, CAR T-cell therapy access gaps, myeloma advances, and bispecific therapy challenges.

Experts examined oncology care innovation, access gaps to CAR T-cell therapy, advances in myeloma care, and partnerships in value-based care.

Justin Favaro, MD, discusses independent oncology models, ACA challenges, and strategies to reduce health care costs at IVBM Charlotte 2026.

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.

Discussion covered lung cancer biomarker testing, care in hematologic malignancies, health equity in cancer screening, and medically integrated pharmacy dispensing

Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.

Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.

Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap.

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.

Equity gaps in lung cancer molecular testing persist; reflex testing and nurse navigation speed care, while coverage and access barriers stall outcomes

Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.

With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it.

Shawn Davis, MD, explains why shifting from BMI to adiposity-based care could transform how health systems allocate resources and reduce obesity-driven hospital costs.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.

Oncology has never had more to offer, and yet it is straining under the weight of its own progress.

Delivering value-based oncology care requires both scientific breakthroughs and deliberate system redesign, experts concurred during this February IVBM in Los Angeles.